These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7082780)

  • 1. Bioavailability of phenylbutazone from a new enteric-coated formulation with superior dissolution characteristics.
    John VA; Goldsborough S; Morrison PJ; Rogers HJ; Spector RG; Bradbrook ID
    Biopharm Drug Dispos; 1982; 3(1):67-74. PubMed ID: 7082780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of antacids on the absorption of enteric-coated phenylbutazone (butacote).
    Downie WW; Lowe JR; Pickup ME
    J Int Med Res; 1977; 5 Suppl 2():20-5. PubMed ID: 913870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability evaluation of an enteric-coated phenylbutazone formulation, and cross-over comparison with a sugar-coated product.
    Triggs EJ; Whyatt PL; Eckert G
    Med J Aust; 1977 Dec; 2(25):830-3. PubMed ID: 613197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The objective and timing of drug disposition studies, appendix IV. Phenylbutazone formulations: in vitro dissolution and in vivo performance.
    Leeson LJ; Shinal EC; Lukas G; Zak SB; Weiner M
    Drug Metab Rev; 1975; 4(2):277-84. PubMed ID: 1222684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The physiologic availability of phenylbutazone tablets marketed in India.
    Manek SP; Tipnis HP; Kulkarni RD
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of food on the absorption of phenylbutazone from a commercial 100 mg enteric-coated tablet.
    John VA; Monk JP
    J Clin Hosp Pharm; 1982 Sep; 7(3):175-9. PubMed ID: 7174832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butacote: the first assessment in general practice.
    Rushford WA; Fowler PD
    J Int Med Res; 1977; 5 Suppl 2():67-9. PubMed ID: 334607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioequivalence of phenylbutazone preparations following a single intramuscular administration].
    Weyhenmeyer R; Dingler E; Lohaus R; Mayer D; Teicher H; Wybitul K; Wangemann G; Steim H
    Arzneimittelforschung; 1984; 34(6):721-3. PubMed ID: 6541493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dosage forms. IV. Studies on commercial phenylbutazone tablet dosage forms.
    Razdan B; Paradkar AR
    Drug Dev Ind Pharm; 1998 Jul; 24(7):599-604. PubMed ID: 9876503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(3):263-76. PubMed ID: 8603
    [No Abstract]   [Full Text] [Related]  

  • 11. The bioavailability of phenylbutazone in the horse.
    Smith PB; Caldwell J; Smith RL; Horner MW; Moss MS
    Xenobiotica; 1987 Apr; 17(4):435-43. PubMed ID: 3604253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers.
    Garg SK; Chugh Y; Tripathi SK; Kumar N; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):96-9. PubMed ID: 8458683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it possible to achieve bio-equivalence between an oral solid immediate-release and an analogue enteric-coated formulation?
    Licht D; Cohen R; Spiegelstein O; Rabinovich-Guilatt L; Zholkovsky M; Gilbert A; Dressman JB; Safadi M
    J Pharm Pharmacol; 2016 Oct; 68(10):1278-89. PubMed ID: 27465906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations.
    Basmenji S; Valizadeh H; Zakeri-Milani P
    Arzneimittelforschung; 2011; 61(10):566-70. PubMed ID: 22164964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
    Bendas ER; Ayres JW
    Eur J Pharm Biopharm; 2008 Aug; 69(3):977-85. PubMed ID: 18424095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets.
    Nishimura K; Sasahara K; Arai M; Nitanai T; Ikegami Y; Morioka T; Nakajima E
    J Pharm Sci; 1984 Jul; 73(7):942-6. PubMed ID: 6088756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butacote: a six-year follow-up of patients with gastric intolerance to other medications.
    Cardoe N; Fowler PD
    J Int Med Res; 1977; 5 Suppl 2():59-66. PubMed ID: 334606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.